Kidney Transplant | Current Treatment | US | 2016
Each year in the United States, more than 17,000 patients suffering from renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. This content stream explores the differences in prescribing practices, attitudes, and perceptions of the general nephrologists, transplant nephrologists, and transplant surgeons involved in kidney patients’ continuum of care and uncovers potential opportunities in the marketing of current and future immunosuppressant therapies.
Related Market Assessment Reports
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
